Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine

Hecq, Jérôme; Deleers, Michel; Fanara, D.; Vranckx, Henri; Amighi, Karim

doi:10.1016/j.ijpharm.2005.05.014

Cited by 294 publications

(150 citation statements)

References 22 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…[17] An excess amount of glimepiride and solid dispersions were added to 20 mL of freshly prepared distilled water in clean vials with continuous shaking on a Remi mini rotary shaker-12R-DX at 25 ± 0.5 °C for 24 h to achieve equilibrium. The filtered solutions were suitably diluted and analyzed spectrophotometrically.…”

Section: Solubility Measurement Of Solid Dispersionsmentioning

confidence: 99%

Improvement in Micromeritic Properties and Dissolution Rate of Glimepiride

Sahoo¹

2017

WJPR

View full text Add to dashboard Cite

show abstract

Section: Solubility Measurement Of Solid Dispersionsmentioning

confidence: 99%

Improvement in Micromeritic Properties and Dissolution Rate of Glimepiride

Sahoo¹

2017

WJPR

View full text Add to dashboard Cite

show abstract

“…Pure nifedipine poorly dissolves, with less than 15% dissolved after 60 min, under the dissolution conditions used for the tests [24] : the hydrophobic property of the drug molecule prevents its wettability by the dissolution medium. The dissolution profiles concerning the co-precipitates indicate that, as the concentration of polymer in the co-precipitate increases, the release of nifedipine also increases compared to the pure drug.…”

Section: Release Of Nifedipine From Soluplus Co-precipitatesmentioning

confidence: 99%

Release Problems for Nifedipine in the Presence of Soluplus

Fini¹,

Cavallari²,

Ternullo³

et al. 2016

JPP

View full text Add to dashboard Cite

Nifedipine/soluplus co-precipitates were prepared at 1:9 and 1:1 weight ratios, using the solvent method, with the aim to obtain an improvement of the drug release. The release, though accelerated with respect to physical mixtures and pure drug, resulted slow with respect to similar systems containing soluplus and are characterized by the appearance in suspension of micro-particulates that, at the optical microscope, revealed a large variety of shapes typical of flower-like aggregates, not previously reported. For comparison systems were also prepared with PVP K30 and sucrester P1670 and two mixtures, without any evidence of this last phenomenon. The systems were studied by thermal (differential scanning calorimetry -DSC, thermomicroscopy -HSM) and spectroscopic (SEM, FT-IR, micro-Raman) analysis. Slow release of nifedipine and formation of colloidal micro-particulates were hypothesized due to the gelling tendency of soluplus associated to drug/polymer multi-site-interactions: when one of these parameters is absent in the system the two phenomena could not be observed together, such as in the case of PVP K30 or sucrester P1670, when used as carriers for nifedipine release.

show abstract

“…For some drugs, the dissolution rate can be a limiting factor for their efficacy, i.e., nifedipine (28) or itraconazole (36). TMZ is a compound that is very slightly soluble in water and some strategies are performed in order to overcome this problem (37).…”

Section: Release Profile Of Tmz From Dry Powder Formulationsmentioning

confidence: 99%

Temozolomide-Based Dry Powder Formulations for Lung Tumor-Related Inhalation Treatment

et al. 2010

View full text Add to dashboard Cite

Purpose Temozolomide dry powder formulations for inhalation, performed with no excipient or with a lipid or lactose coating, have been evaluated. MethodsThe particle size of raw Temozolomide in suspension was reduced by means of a high-pressure homogenizing technique and the solvent was evaporated by spray-drying to obtain a dry powder. Physicochemical properties (crystalline state, thermal properties, morphology, particle size and moisture and drug content) were determined by means of X-ray powder diffraction, differential scanning calorimetry, scanning electron microscopy, laser light scattering, thermogravimetric analysis and high-performance liquid chromatography, respectively. Aerodynamic properties and release profiles were also evaluated using a multistage liquid impinger and a modified USP type 2 dissolution apparatus adapted to inhaler products, respectively. ResultsThe dry powder formulations for inhalation had a high temozolomide content that ranged from 70 % to 100%, remains the temozolomide crystalline state and had a low moisture content. Aerodynamic evaluations showed high fine particle fractions of up to 51% related to the metered dose. The dissolution profile revealed a similarly fast temozolomide release from the formulations. Conclusions

show abstract

Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine

Cited by 294 publications

References 22 publications

Improvement in Micromeritic Properties and Dissolution Rate of Glimepiride

Improvement in Micromeritic Properties and Dissolution Rate of Glimepiride

Release Problems for Nifedipine in the Presence of Soluplus

Temozolomide-Based Dry Powder Formulations for Lung Tumor-Related Inhalation Treatment

Contact Info

Product

Resources

About